# IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness

> **NIH ALLCDC U01** · UNIVERSITY OF ROCHESTER · 2024 · $1,234,285

## Abstract

PROJECT SUMMARY/ABSTRACT (COMPONENTS A, B and C):
 Viral acute respiratory infections (ARI) and acute gastroenteritis (AGE) remain major causes of morbidity
in children, making vaccine development and implementation a high public health priority. The overall goal of
the CDC New Vaccine Surveillance Network (NVSN) is to establish a network of US institutions that develop
and implement standard research protocols to answer important questions about the burden of disease and
natural history of vaccine preventable diseases, specifically, those causing ARI and AGE. A second goal of
population-based NVSN surveillance is to provide accurate estimates of vaccine effectiveness (VE) in
preventing pediatric hospitalization or medical care visits. A third goal is the ability to rapidly pivot to study
novel agents such as enterovirus-D68 (EV-D68) or SARS-CoV-2, and syndromes such as acute flaccid
myelitis (AFM) and multisystem inflammatory syndrome in children (MIS-C).
 The proposed work (comprising Mandatory Core A, and Optional Components B and C) will enhance
the NVSN site in Rochester, NY—one of 2 original members of the now 7-site network. For 20 years we have
published important studies on the burden of disease and natural history of AGE due to rotavirus and
norovirus, and ARI due to influenza, (RSV), and other viruses. These data helped inform AAP and ACIP on
pediatric influenza and rotavirus vaccination, and palivizumab use for RSV prevention. Our specific aims are:
 Mandatory Core Component A: Perform prospective, population-based active surveillance for ARIs and
 AGEs in inpatient and ED settings as well as asymptomatic controls, for children 0-18 years. We will use
 molecular diagnostics for rotavirus, norovirus, influenza, RSV, PIV, EV-D68, SARS-CoV-2, and other viruses.
 We will assess VE for influenza, rotavirus, and future SARS-CoV-2 vaccines in preventing pediatric
 hospitalizations and ED visits. We will delineate the disease burden of ARI and AGE using our unique
 capture of virtually all pediatric hospitalizations and ED visits in our region. We will assess the impact of
 future vaccines and other immunoprophylaxis strategies. We will perform active surveillance and
 epidemiologic studies of acute flaccid myelitis (AFM) syndrome in children. Finally, we will perform and lead
 epidemiological, implementation and laboratory studies based on population-based NVSN surveillance.
 Optional Component B: Implement active prospective population-based ARI/AGE surveillance studies in
 children seeking medical care in outpatient practices, as the burden of ARI and AGE are likely high.
 Optional Component C: Investigate the incidence, spectrum of disease, and risk factors associated with
 SARS-CoV-2 MIS-C.
 Our proposed research will provide high impact information to develop sound policies for the prevention
of pediatric vaccine-preventable diseases, and to improve the health of US children.

## Key facts

- **NIH application ID:** 11046486
- **Project number:** 5U01IP001158-04
- **Recipient organization:** UNIVERSITY OF ROCHESTER
- **Principal Investigator:** Geoffrey Alan Weinberg
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2024
- **Award amount:** $1,234,285
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11046486

## Citation

> US National Institutes of Health, RePORTER application 11046486, IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness (5U01IP001158-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11046486. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*